Recent research have centered on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and DA signaling. While GLP activators are widely employed for managing type 2 T2DM, their emerging consequences on reward circuits, specifically influenced by dopamine networks, are receiving considerable focus. This report det